Skip to contentE
Enveric Biosciences, Inc.
E
ENVBEnveric Biosciences, Inc. Q1 2021 · 10-Q
Revenue—
Net Income-$3.25M-$3.25MN/M vs Q1 2020 EPS Diluted-$0.20-$0.20N/M vs Q1 2020 Operating Income-$6,764,997N/M Operating Cash Flow-$3,162,278N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Enveric Biosciences, Inc. · CIK 890821 · Engraved from SEC EDGAR
ended Mar 31, 2021 · filed May 17, 2021 · 47 d after period end